Clinical trials: PAD - Peripheral Arterial Disease
Peripheral Artery Disease, Peripheral Vascular Disease
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
Collect confirmatory evidence of the safety and effectiveness of the Balloon LIFESTREAM™ Stent Graft for the treatment of stenoses and occlusion in the iliac arteries.
- Conditions
- Peripheral Artery Disease, Peripheral Vascular Disease, Arterial Occlusive Disease
- Trial name
- BOLSTER (NCT02228564)
- Testing
- Percutaneous transluminal angioplasty (PTA), LIFESTREAM™ covered stent
- Where
- 20 sites in United States, Germany and 1 more
- Volunteers
- 155 people
- Sponsor
- C. R. Bard
Peripheral Artery Disease
CELLO - CLiRpath® Excimer Laser System to Enlarge Lumen Openings
The objective of this study is to evaluate the safety and efficacy of the CLiRpath® Photoablation Atherectomy System consisting of the Bias Sheath guiding catheter, in combination with the available CLiRpath® Excimer Laser…
- Trial name
- CELLO (NCT00595959)
- Testing
- CLiRpath Photoablation System
- Volunteers
- 65 people
- Sponsor
- Spectranetics Corporation
Critical Limb Ischemia
A Safety and Tolerability Study of RJX Drug Product in Healthy Participants
Designed as a single center, two-part, double-blind, placebo-controlled, randomized study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RJX in healthy participants.
- Trial name
- NCT03680105
- Testing
- RJX
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Reven Pharmaceuticals, Inc.
Peripheral Artery Disease
ILLUMENATE Pivotal Post-Approval Study (PAS)
The ILLUMENATE Pivotal PAS is a continued follow-up study which will include 300 subjects from forty-three (43) sites across the United States and Austria previously enrolled in the ILLUMENATE Pivotal pre-market study to evaluate…
- Trial name
- NCT03421561
- Testing
- Stellarex 0.035" OTW Drug-coated Angioplasty Balloon, EverCross™ 0.035 PTA Balloon Catheter
- Where
- 41 sites in United States, Austria
- Volunteers
- 300 people
- Sponsor
- Spectranetics Corporation
Peripheral Arterial Disease
Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
Shockwave Medical Inc. intends to conduct a prospective, multi-center, single blind, randomized (1:1) study of Lithoplasty treatment used in combination with DCB versus standard balloon angioplasty used in combination with DCB to…
- Trial name
- NCT02923193
- Testing
- Shockwave Lithoplasty® Peripheral Lithoplasty System, Medtronic IN.PACT (DCB)
- Where
- 54 sites in United States, Austria and 2 more
- Volunteers
- 306 people
- Sponsor
- Shockwave Medical, Inc.
PAD - Peripheral Arterial Disease, PVD- Peripheral Vascular Disease
Electrical Stimulation as an Adjunctive Therapy to Increase Vascular Perfusion in People With PAD or PVD
The purpose of this study is to apply Avazzia micro-current stimulation to patients with chronic, non-healing wounds to determine if this therapy is effective in perfusion and bacterial measurements.
- Trial name
- NCT04313985
- Testing
- Tennant Biomodulator-Pro™ Device
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Peripheral Arterial Disease, Peripheral Artery Disease
Implementation of Telemedicine for Patient With Lower Extremity Wounds
The objective of this study is to determine if patients with lower extremity wounds in rural communities who undergo specialty referral through telemedicine have expedited care compared to patients who are treated through…
- Conditions
- Peripheral Arterial Disease, Peripheral Artery Disease, Peripheral Vascular Diseases, Diabetic Foot
- Trial name
- NCT04440839
- Testing
- Telemedicine specialty consultation
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- University of California, Davis
Peripheral Arterial Disease, Diabetic Foot Ulcer
Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers
This Phase 1, multicenter, open-label, dose-escalation study evaluated the safety and tolerability of intramuscular administration of PDA-002 (human placenta-derived cells) in subjects with peripheral arterial disease (PAD) and…
- Trial name
- NCT01859117
- Testing
- PDA-002
- Where
- 12 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celularity Incorporated
Peripheral Artery Disease, Peripheral Vascular Disease
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The objective of this study is to separately demonstrate the safety and efficacy of BIOTRONIK's Astron and Pulsar stents. The Pulsar stent will be used for the treatment of femoro-popliteal lesions, located in the native…
- Trial name
- BIOFLEX-I (NCT01319812)
- Testing
- Astron Stents, Pulsar Stents
- Where
- 35 sites in United States, Canada
- Volunteers
- 463 people
- Sponsor
- Biotronik, Inc.
Peripheral Arterial Disease
Nitrites, Exercise, and Peripheral Arterial Disease
The hypothesis of this proposal is that in subjects with PAD, regular consumption of a high nitrate supplement which raises plasma nitrite, in conjunction with 12 weeks of supervised exercise training at the limb ischemic…
- Trial name
- NO-PAD (NCT01684930)
- Testing
- Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Arterial Occlusive Disease, Peripheral Vascular Disease
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
The objective of this study is to test the hypothesis that AMG0001 treatment is safe and induces angiogenesis as detected by improved wound healing, reduction in amputation, improved pain at rest and hemodynamic measurement and…
- Conditions
- Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia, Ulcers
- Trial name
- NCT00189540
- Testing
- HGF plasmid
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- AnGes USA, Inc.
Critical Limb Ischemia, Peripheral Arterial Disease
IN.PACT BTK Randomized Study to Assess Safety and Efficacy of IN.PACT 014 vs. PTA
To assess the safety and efficacy of the paclitaxel drug-coated balloon IN.PACT 014 versus conventional optimal percutaneous transluminal angioplasty (PTA) for the treatment of patients with chronic total occlusions in the…
- Trial name
- NCT02963649
- Testing
- DCB, PTA
- Where
- 9 sites in Belgium, France and 3 more
- Volunteers
- 50 people
- Sponsor
- Medtronic Endovascular
Type 2 Diabetes, Peripheral Arterial Disease
Liraglutide and Peripheral Artery Disease
STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with…
- Trial name
- STARDUST (NCT04881110)
- Testing
- Liraglutide, Control
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Peripheral Arterial Disease, Intermittent Claudication
High Intensity Interval Training In pATiEnts With Intermittent Claudication
This INITIATE study evaluates the use of high-intensity interval training as a treatment modality for patients with intermittent claudication - an ambulatory leg pain caused by narrowed arteries that supply the lower limbs.
- Trial name
- INITIATE (NCT04042311)
- Testing
- High-intensity interval training
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Diabetes Mellitus, Type 2, Peripheral Arterial Disease
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes.
- Trial name
- STRIDE (NCT04560998)
- Testing
- Semaglutide
- Where
- 283 sites in United States, Austria and 19 more
- Volunteers
- 792 people
- Sponsor
- Novo Nordisk A/S
Peripheral Arterial Disease
Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME II)
The purpose of this study is to evaluate the safety and effectiveness of the Jetstream Atherectomy System for the treatment of Japanese patients with symptomatic occlusive atherosclerotic lesions in native superficial femoral…
- Trial name
- NCT03847233
- Testing
- Jetstream Atherectomy System
- Where
- 5 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Boston Scientific Corporation
Peripheral Artery Disease
Framing Clinical Trial Enrollment for Patients With Peripheral Artery Disease
It is uncertain whether opt-out framing will increase participation in a clinical trial intended to promote physical activity in patients with peripheral artery disease (PAD).
- Trial name
- NCT04536038
- Testing
- Opt-out
- Where
- United States
- Volunteers
- 5,176 people
- Sponsor
- University of Pennsylvania
Peripheral Artery Disease (PAD); Intermittent Claudication
Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
This study is designed to determine whether LLG783 displays the clinical safety and efficacy profile, after multiple i.v. doses, to support further development in patients with PAD and intermittent claudication.
- Trial name
- PAD PoC (NCT03194776)
- Testing
- LLG783
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Peripheral Arterial Disease
Edoxaban in Peripheral Arterial Disease
This study is a randomized, open-label, blinded endpoint, parallel-group, active-control, multi-center, proof-of-concept study in subjects with Peripheral Arterial Disease (PAD), designed to assess the safety and potential…
- Trial name
- ePAD (NCT01802775)
- Testing
- edoxaban, Clopidogrel, Aspirin
- Where
- 42 sites in United States, Austria and 5 more
- Volunteers
- 203 people
- Sponsor
- Daiichi Sankyo
Myocardial Infarction, Diabetes Mellitus
Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor, more frequently clopidogrel, represents the standard of care for the long-term secondary prevention of atherothrombotic events in patients with…
- Conditions
- Myocardial Infarction, Diabetes Mellitus, Peripheral Arterial Disease
- Trial name
- OPTIMUS-5 (NCT02548650)
- Testing
- Vorapaxar, Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Florida